Longitudinal changes in patient-reported dyspnea in patients with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 5, 2012, Pages 522-527

  Mahler, Donald A ^a   Ward, Joseph ^a   Waterman, Laurie A ^a   Baird, John C ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Psychological Applications   (United States)

Author keywords

; Transition dyspnea index; Impact of daily activities on dyspnea; Modified Medical Research Council scale; Monitoring symptoms; University of California San Diego shortness of breath questionnaire.

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DISEASE COURSE; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PATIENT REPORTED DYSPNEA; PRIORITY JOURNAL; SELF ADMINISTERED COMPUTERIZED TRANSITION DYSPNEA INDEX; SPIROMETRY; UNIVERSITY OF CALIFORNIA SAN DIEGO SHORTNESS OF BREATH QUESTIONNAIRE;

ACTIVITIES OF DAILY LIVING; AGED; COHORT STUDIES; DISEASE PROGRESSION; DYSPNEA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SELF REPORT; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84867083577     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.701678     Document Type: Article

References (47)

1. van den Bemt L, Schermer T, van Weel C. Rational monitoring of COPD: where do current clinical guidelines stand? Eur Respir J 2007; 29(6):1078-1081.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6):532-555.
3. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932- 946.
4. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, et al. Canadian Th oracic Society recommendations for management of chronic obstructive pulmonary disease ó 2007 update. Can Respir J 2007; 14 Suppl B:5B-32B.
5. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Th oracic Society, and European Respiratory Society. Ann Intern Med 2011; 155(3):179-191.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. At: www.goldcopd.com [accessed 1 March 2012].
7. Mahler DA. Measurement of Dyspnea: Clinical Ratings. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. 2nd ed. Boca Raton, FL: Taylor & Francis; 2005: 147-165.
8. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31(2):416-469.
9. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27(4):822-832.
10. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2):217-224.
11. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6):912-919.
12. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Effi cacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1):74-81.
13. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Effi cacy of a new once-daily long-acting inhaled beta2- agonist indacaterol versus twice-daily formoterol in COPD. Th orax 2010; 65(6):473-479.
14. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775-789.
15. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543-1554.
16. Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O'Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151(1):61-65.
17. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Eff ects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122(11):823-832.
18. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007;101(1):146-153.
19. Brooks SM. Task group on surveillance for respiratory hazards in the occupational setting. ATS News. 1982; 8:12-16.
20. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 2007; 132(4):1283-1290.
21. Mahler DA, Ward J, Fierro-Carrion G, Waterman L, Lentine TF, Mejia-Alfaro R, et al. Development of self-administered versions of the modifi ed baseline and transition dyspnea indexes in COPD. J COPD 2004; 1:165-172.
22. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113(3):619-624.
23. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971; 103(1):57-67.
24. Diggle PJ, Heagerty P, Liang K, Zeger SL, eds. Analysis of Longitudinal Data. 2nd ed. Oxford University Press New York; 2002.
25. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An Offi cial American Th oracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. Am J Respir Crit Care Med 2012; 185(4):435-452.
26. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Eff ectiveness of fl uticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084-1091.
27. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10): 1005-1012.
28. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182(2):155-162.
29. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al. Rofl umilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374(9691):695-703.
30. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The effi cacy and safety of fl uticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834-843.
31. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26(4):630-636.
32. Witek TJ, Jr, Mahler DA. Meaningful eff ect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56(3):248-255.
33. Mahler DA, Witek TJ, Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2(1):99-103.
34. Ries AL. Minimally clinically important diff erence for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2(1):105-110.
35. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003; 67(6):880-888.
36. California Pulmonary Rehabilitation Collaborative Group. Eff ects of pulmonary rehabilitation on dyspnea quality o fl ife and health care costs in California. J Cardiopulm Rehab 2004; 24:52-62.
37. Stulbarg MS, Carrieri-Kohlman V, Demir-Deviren S, Nguyen HQ, Adams L, Tsang AH, et al. Exercise training improves outcomes of a dyspnea self-management program. J Cardiopulm Rehabil 2002; 22(2):109-121.
38. Criner GJ, Sharafkhaneh A, Player R, Conoscenti CS, Johnson P, Keyser MT, et al. Effi cacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD 2008; 5(1):35-41.
39. de Torres JP, Pinto-Plata V, Ingenito E, Bagley P, Gray A, Berger R, et al. Power of outcome measurements to detect clinically signifi cant changes in pulmonary rehabilitation of patients with COPD. Chest 2002; 121(4):1092-1098.
40. Fletcher C, Peto R. Natural history of chronic respiratory tract obstruction. Bull Int Union Tuberc 1978; 53(2):79-87.
41. Casanova C, de Torres JP, Aguirre-Jaime A, Pinto-Plata V, Marin JM, Cordoba E, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011; 184(9):1015-1021.
42. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365(13):1184-1192.
43. Celli BR, Th omas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Eff ect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178(4):332-338.
44. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Eff ect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecifi ed subgroup analysis of a randomised controlled trial. Lancet 2009; 374(9696):1171-1178.
45. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174(1):6-14.
46. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebocontrolled trial. Respir Med 2008; 102(4):479-487.
47. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25):2655-2666.